Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20060018938 A1
Publication typeApplication
Application numberUS 11/180,913
Publication dateJan 26, 2006
Filing dateJul 14, 2005
Priority dateAug 18, 1997
Also published asCA2300054A1, CA2300054C, EP1014916A2, EP1014916B1, EP1014916B2, US6423323, US20020001599, US20030059394, US20080213193, WO1999008649A2, WO1999008649A3
Publication number11180913, 180913, US 2006/0018938 A1, US 2006/018938 A1, US 20060018938 A1, US 20060018938A1, US 2006018938 A1, US 2006018938A1, US-A1-20060018938, US-A1-2006018938, US2006/0018938A1, US2006/018938A1, US20060018938 A1, US20060018938A1, US2006018938 A1, US2006018938A1
InventorsFritz Neubourg
Original AssigneeStephanie Neubourg
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Foam skin cream, use of the foam skin protection cream and a process of its preparation
US 20060018938 A1
Abstract
A foam skin cream can be obtained by
  • preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, emulsifiers, coemulsifiers, such as triceteareth-4-phosphate, followed by metering it with stirring to a phase II temperature-controlled at 75° C. obtained from an aqueous mixture containing moisturizers, such as propylene glycol and/or polyhydric alcohols, especially glycerol, emulsifiers, such as alkyl sarcosinates, and skin care additives, such as allantoin; wherein homogeneous mixing of phases I and II is provided and said metering is performed at a temperature of 75° C.; after the metered addition, the temperature is maintained at 75° C. for a period of between 5 and 20 minutes; whereupon the temperature of the thus obtained mixture is lowered to a temperature of between 30 and 40° C. with constant stirring; the pH value is adjusted to from 7.6 to 8.2, preferably with a skin-compatible basic organic compound, and the mixture obtained is filled into dosage forms with the addition of a propellant.
Images(5)
Previous page
Next page
Claims(12)
1-17. (canceled)
18. A foam aerosol skin cream, wherein the skin cream does not contain PTFE, obtained by
preparing a phase I by melting at 75° C. a mixture containing one or more C10-C22 fatty acids, optionally containing an unsaturated or polyunsaturated fatty acid, an emulsifier, or a coemulsifier or a mixture thereof;
preparing a phase II, temperature-controlled at 75° C., by aqueous admixture of urea, as a moisture-binding agent, and two or three ingredients selected from the group consisting of a moisturizer, an emulsifier, and a skin care additive, and a combination thereof;
metered addition with homogenous mixing of phase I and phase II at a temperature of 75° C.; followed by
maintaining the temperature of the homogeneous mixture at 75° C. for a period of between 5 and 20 minutes; followed by
lowering the temperature of the homogeneous mixture from 75° C. to a temperature between 30° C. and 40° C. with constant stirring; followed by
adjusting the pH of the homogeneous mixture at a temperature between 30° C. and 40° C. to a value of 7.6 to 8.2; followed by
combining the homogeneous mixture with a propellant in a dosage form, wherein the propellant is butane, propane, or a mixture thereof.
19. The foam aerosol skin cream according to claim 18, wherein phase I further contains as a coemulsifier triceteareth-4-phosphate.
20. The foam aerosol skin cream according to claim 18, wherein the moisturizer in phase II is propylene glycol, a polyhydric alcohol, or a combination thereof.
21. The foam aerosol skin cream according to claim 18, wherein the moisturizer in phase II is glycerol and the emulsifier in phase II is an alkyl sarcosinate.
22. The foam aerosol skin cream according to claim 18, wherein the skin care additive in phase II is allantoin.
23. The foam aerosol skin cream according to claim 18, wherein the pH is adjusted to a value from of 7.6 to 8.2 by adding a skin-compatible basic organic compound.
24. The foam aerosol skin cream according to claim 18, further comprising adding a preservative to the homogeneous mixture, with stirring, at the temperature of 30° C. to 40° C.
25. The foam aerosol skin cream according to claim 18, containing
from 4 to 15% by weight of oil-in-water emulsifier;
from 1 to 10% by weight of the C10-C22 fatty acid;
from 0.4 to 2.3% by weight of the coemulsifier;
from 1 to 20% urea;
from 1 to 10% by weight of the moisturizer;
from 0.5 to 1% by weight of the skin care additive; and
water as the balance to make 100% by weight.
26. A process for making the foam aerosol skin cream comprising:
preparing a phase I by melting at 75° C. a mixture containing one or more C10-C22 fatty acids, optionally containing an unsaturated or polyunsaturated fatty acid, an emulsifier, or a coemulsifier or a mixture thereof;
preparing a phase II, temperature-controlled at 75° C., by aqueous admixture of urea, as a moisture-binding agent, and two or three ingredients selected from the group consisting of a moisturizer, an emulsifier, and a skin care additive, and a combination thereof;
metered addition with homogenous mixing of phase I and phase II at a temperature of 75° C.; followed by
maintaining the temperature of the homogeneous mixture at 75° C. for a period of between 5 and 20 minutes; followed by
lowering the temperature of the homogeneous mixture from 75° C. to a temperature between 30° C. and 40° C. with constant stirring; followed by
adjusting the pH of the homogeneous mixture at a temperature between 30° C. and 40° C. to a value of 7.6 to 8.2.
27. The foam aerosol skin cream made by the process according to claim 26.
28. A process of making a container of spray foam aerosol cream comprising filling the foam aerosol cream of claim 27 together with a propellant into a spray-can container, wherein the propellant is butane, propane, or a mixture thereof.
Description
  • [0001]
    The present invention relates to a foam skin cream, uses of the foam skin protection cream and a process for its preparation.
  • [0002]
    The galenic principle of an emulsoid two-phase system having lipophilic or hydrophobic components and, on the other hand, hydrophilic components has been known for the production of foam preparations for skin care. The application of these foam preparations to the treated skin forms a two-dimensional two-phase network, the hydrophilic components bind to the keratin of the horny layer and enable the evaporation of sweat while the lipophilic components inhibit the permeation of moisture (including the penetrated sweat) on the skin surface. As the foam, in contrast to other creams building a barrier, is absorbed in less than a minute, does not leave any grease traces on the working materials and prevents heat built-up or even maceration effects from the action of sweat, the foam has enjoyed rapidly growing popularity as a protective agent against occupational action of moisture. Further details about the per se known foam skin creams can be seen, in particular, from “Haut”, issue 4, 1992, by R. Rudolph, L. Bade, B. Brüggemann.
  • [0003]
    In “hautnah derm” 10 (1994), 344-351, B. Kunze reports lipid-containing skin protection foams which are indicated for dry sensitive skin and chronical-rhagadiform eczemas. Ingredients are also disclosed therein. The skin protection foams described therein are protective against a lot of occupational noxious matters, such as acid permanent waving liquids in the hairdresser's trade, lyes, oils, disinfectants, cleaning and rinsing agents, but also against water, moisture, sweat, feces, urine and mineral dusts.
  • [0004]
    EP 0 598 412 also relates to skin protection foams; PTFE is described as an active principle.
  • [0005]
    DE-C-33 30 628 relates to skin protection and care-lotions containing silicone oils, partially neutralized stearic acid, fatty alcohols and their ethoxylated derivatives, ethoxylated wool alcohols, cetyl/stearyl alcohol, vaseline, thickeners and water. The lotions disclosed therein are said to be quickly absorbed without leaving an annoying grease film on the skin for extended periods of time.
  • [0006]
    Information about emulsifiers which can be employed in skin care agents are found in DE-A-195 42 572. This reference suggests emulsifiers which contain from 43 to 90% by weight of alkyl and/or alkenyl oligoglycosides and from 10 to 57% by weight of fatty alcohols. These emulsifiers are particularly suitable for the preparation of highly viscous, sensorily light oil-in-water emulsions having a long shelf life. The German utility model DE-U-9308050 relates to a skin protection foam used against skin-aggressive agents. This foam consists of an aqueous emulsion containing fatty acid esters with good skin compatibility for the production of a moisture-permeable film, polyhydric alcohol for stably dispersing the active agents and controlling the humidity of the film, emulsifiers for improving foam stability, surfactants for reducing the surface tension and optionally neutralizing agents for resins and emulsifiers. Gaseous hydrocarbons may be used as propellants, for example, propane, butane or isobutane and mixtures thereof. However, the foams described do not contain any free fatty acids.
  • [0007]
    Aerosoles are complicated physical-chemical structures which do not form under arbitrary circumstances. In Particular, a special balance between the foam-forming components is important. Slight shifts in the composition may already result in a collapse of the foam; thus, a formulation of per se active substances may not be capable of being formulated as a foam without further provisions.
  • [0008]
    Especially in occupational applications, skin creams are often found unpleasant because the “fatting” components remain too long on the skin and lead to annoying finger traces or generally to an unpleasant feeling. This has been remedied to some extent by the per se known skin foams since they help preventing or reducing overload of the skin with the fatting matters. Nevertheless, it is desirable to find even more acceptance by the user, especially in the long-term use of skin protection agents.
  • [0009]
    It has been the object of the present invention to extend the application range of skin protection foams by providing a formulation which is highly accepted by the user, the admixture of a wide variety of other substances being allowed without destroying the aerosol employed or deteriorating the properties of the aerosol.
  • [0010]
    The object of the invention is surprisingly achieved by a base formulation of a foam skin cream having the features of claim 1. Dependent claims 2 to 12 relate to preferred embodiments of the foam skin cream according to the invention. Claims 13 to 16 relate to uses of the foam skin cream according to the invention, whereas claim 17 relates to a process for preparing the base of a foam skin cream according to the invention.
  • [0011]
    The foam skin cream according to the invention can be obtained by
    • preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, emulsifiers, coemulsifiers, such as triceteareth-4-phosphate, followed by metering it with stirring to
    • a phase II temperature-controlled at 75° C. obtained from an aqueous mixture containing moisturizers, such as propylene glycol and/or polyhydric alcohols, especially glycerol, emulsifiers, such as alkyl sarcosinates, and skin care additives, such as allantoin;
    • wherein homogeneous mixing of phases I and II is provided and said metering is performed at a temperature of 75° C.;
    • after the metered addition, the temperature is maintained at 75° C. for a period of between 5 and 20 minutes; whereupon the temperature of the thus obtained mixture is lowered to a temperature of between 30 and 40° C. with constant stirring;
    • the pH value is adjusted to from 7.6 to 8.2, preferably with a skin-compatible basic organic compound, and the mixture obtained is filled into dosage forms with the addition of a propellant.
  • [0017]
    At the one hand, the product obtainable according to this process can be directly employed as a foam skin cream in the industrial field for the protection from or reduction of the absorption of cancerogenic substances, such as polycyclic aromatic hydrocarbons. This mixture is capable of providing effective protection for persons whose skin has already been exposed to cancerogenic substances, such as polycyclic aromatic hydrocarbons. In addition, the mixture is suitable for providing protection to persons from the action of acids, lyes (not above pH 11), scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
  • [0018]
    The foam skin cream according to the invention contains fatty acids, especially C12-C22 fatty acids, and may optionally additionally contain unsaturated and/or polyunsaturated fatty acids. Useful fatty acids which are saturated include, in particular, the naturally occurring C12-C22 fatty acids, especially stearic acid and palmitic acid. Myristic acid may also be used. Useful unsaturated fatty acids include, in particular, those having up to three unsaturated bonds in their hydrocarbon chain. Unsaturated fatty acids are found, for example, in fractions of coconut fat. Useful coemulsifiers include per se known coemulsifiers, especially triceteareth-4-phosphate, sodium laureth-4-phosphate or oleth-3 and other lipophilic emulsifiers based on fatty alcohols with a low degree of ethoxylation.
  • [0019]
    Phase I may additionally contain paraffinum liquidum. Emulsifiers to be used in phase I may include those based on fatty alcohols and those based on partial esters of fatty acids. Particularly preferred fatty alcohols include cetearyl alcohol. Glyceryl stearate, for example, may be employed as a partial ester of a fatty acid.
  • [0020]
    The moisturizers to be used in phase II include, in particular, propylene glycol and/or polyhydric alcohols, such as glycerol. As particular emulsifiers to be used in phase II, there may be mentioned alkyl sarcosinates, such as lauroyl, lauryl, cetyl sarcosinates.
  • [0021]
    The mixture obtainable according to claim 1 also serves as a base for other foam skin creams which may be employed in a wide range of applications for protecting the skin and alleviating dermatological dysfunctions.
  • [0022]
    If desired, one or more preservatives may be added to the foam skin cream according to the invention. In particular, substances such as methyldibromoglutaronitrile and/or phenoxyethanol have proven to be suitable preservatives. These substances may be added in amounts of from 0.01 to 1% by weight.
  • [0023]
    Preferably, the emulsifiers, fatty acids, coemulsifiers, moisturizers and skin care agents, especially allantoin, panthenol etc., are used in the following amounts:
    • from 4 to 15% by weight of oil-in-water emulsifier;
    • from 1 to 10% by weight of fatty acid, especially from 4 to 7% by weight, preferably from 4.5 to 6% by weight;
    • from 0.4 to 2.3% by weight of coemulsifier;
    • from 1 to 10% by weight of moisturizer;
    • from 0.05 to 1% by weight of skin care agent; and
    • water as the balance to make 100% by weight.
  • [0030]
    A preferable foam skin cream according to the invention contains:
    • from 1 to 3% by weight of glyceryl stearate;
    • from 3 to 6% by weight of cetearyl alcohol;
    • from 4 to 6% by weight of stearic acid;
    • from 0.5 to 2% by weight of paraffin;
    • from 0.4 to 2.3% by weight of triceteareth-4-phosphate;
    • from 1.5 to 4% by weight of propylene glycol;
    • from 1.3 to 4.2% by weight of glycerol;
    • from 1 to 3% by weight of cetyl sarcosinate;
    • from 0.05 to 1% by weight of allantoin; and
    • water as the balance to make 100% by weight.
  • [0041]
    In another preferred embodiment, the foam skin cream according to the invention additionally contains a silicone-containing substance, such as dimethicone. This substance is added to phase I. Preferably, it is present in amounts of from 0.05 to 1% by weight.
  • [0042]
    In addition, the foam skin cream according to the invention may additionally contain one or more refatting substances in phase I, such as decyl oleate, isohexadecane, stearic acid glycol ester, coconut fatty acid ethanolamide, corn oil, peanut oil, almond oil, sesame oil, olive oil, jojoba oil, soybean oil, wool wax alcohols, paraffin, medium-chain triglycerides, oleic acid oleyl esters, white petrolatum, macrogol-glycerol hydroxystearate, hydrogenated castor oil, castor oil from Ricinus communis, avocado oil, wheat germ oil, palmitic acid isopropyl ester, cetyl palmitate, myristic acid myristyl ester and/or octyldodecanol.
  • [0043]
    In particular, the foam skin cream contains amounts of from 0.5 to 2% by weight of decyl oleate and/or from 0.5 to 2% by weight of octyldecanol, or another of the refatting substances mentioned, if the product is to be used for normal skin. The total amount of refatting substances is to be such that the skin protection foam is not destroyed. An amount of about 4% by weight of refatting substances is sufficient for normal to slightly dry skin. If dry skin is to be treated with the foam skin cream according to the invention, amounts of from 3 to 6% by weight of a component of the refatting substances, such as, in particular, decyl oleate and/or octyldecanol, are recommendable. If more than one component is used, the total amount of refatting components is to be about 12% at most for slightly dry skin. If even more severely dry skin is treated, the amount of refatting substances is from about 6 to 9% by weight if a component such as decyl oleate is used, and from 6 to 9% by weight if octyldecanol is used. The amount of refatting substance may then be up to 20% by weight.
  • [0044]
    Like the products without silicone-containing substances, the latter foam skin creams are suitable for the care and protection of the skin, especially from aggressive substances, such as scouring agents and detergents, sweat, urine, stool, rubber gloves, dusts, house dust, machine, drilling and cooling oils, greases, paints/varnishes, gypsum and other substances and chemicals, especially aggressive substances and chemicals.
  • [0045]
    The foam skin creams are also suitable for the treatment or alleviation of dermatological diseases. This includes, in particular, dermatological diseases such as allergic contact dermatitis type I and IV, cumulative-subtoxic eczema, toxic-irritative eczema, microbial-dysregulative eczema, atopic dermatitis, atopic palmoplantar eczema, dyshidrosis, hyperhidrosis, contact urticaria, intertriginous eczema in connection with hemorrhoids, various weeping fungal infections, e.g., interdigital mycosis, perleches, psoriasis vulgaris, ulcus cruris, cholinergic urticaria, diaper dermatitis.
  • [0046]
    It may be indicated to include substances which can increase the moisture content of the skin, in addition to refatting substances. Such hydratizing substances include, in particular, urea, ethoxydiglycol, sodium chloride, magnesium chloride, sorbitol, dexpanthenol, sodium lactate, allantoin, hyaluronic acid, vitamin E, linolenic acid. The amount of those substances can be from 1 to 20% by weight or more of the respective substances, depending on the severity of the disease to be treated. These quantities also apply, in particular, to urea which may also be present in amounts of from 3 to 15% by weight or from 12.5 to 15% by weight. The foam skin cream according to the invention may also be used for psoriasis.
  • [0047]
    One particularly important field of application concerns the prophylaxis and treatment of diabetic foot. Due to accompanying symptoms of diabetes, diabetics suffer from dry skin which in the course of the diseases favors damage to the extremities, up to an extent where amputation becomes necessary in the case of those having been diabetic for many years. Prophylactic application of skin protection agents which provide an improvement of the skin parameters in diabetics can prevent the development of diabetic foot.
  • [0048]
    In addition, skin care substances, such as polyunsaturated fatty acids (PUFA), may be added to the foam skin cream according to the invention. These include, in particular, omega-6 fatty acids as known, for example, from evening primrose oil and borage oil. Both synthetic omega-6 fatty acids and those obtained from the mentioned plant extracts may be employed.
  • [0049]
    Further, there may be used soothing substances, such as chamomile extract, as another fraction which may be admixed with the foam skin cream according to the invention.
  • [0050]
    Skin-active vitamins, such as vitamins A, E and F, may be admixed with the foam skin cream according to the invention in effective amounts. Especially for the treatment and prevention of diaper dermatitis, admixing the following substances has proven useful: from 3 to 7% by weight of Calendula extract, from 3 to 7% by weight of Hamamelis extract, from 3 to 7% by weight of chamomile extract, from 3 to 7% by weight of tea tree oil extract, from 1 to 5% by weight of decyl oleate, from 1 to 5% by weight of octyldodecanol.
  • [0051]
    The process according to the invention for the preparation of the foam skin protection cream according to the invention comprises the following steps:
    • preparing a phase I by melting at 75° C. a mixture containing fatty acids, especially C12-C22 fatty acids, optionally unsaturated and/or polyunsaturated fatty acids, coemulsifiers, such as triceteareth-4-phosphate, followed by metering this phase with stirring to
    • a phase II molten at 75° C. obtained from an aqueous mixture containing moisturizers, such as propylene glycol and/or polyhydric alcohols, especially glycerol, emulsifiers, such as alkyl sarcosinates, and skin care additives, such as allantoin;
    • wherein homogeneous mixing of phases I and II is provided and said metering is performed at a temperature of 75° C.;
    • after the addition of phase I to phase II, the temperature is maintained at 75° C. for a period of between 5 and 20 minutes; whereupon the temperature of the thus obtained mixture is lowered to a temperature of between 30 and 40° C. with constant stirring;
    • adjusting the pH value to from 7.6 to 8.2, preferably with a skin-compatible basic organic compound, and filling into containers with the addition of a propellant.
  • [0057]
    The invention will be further illustrated by the following Example.
  • EXAMPLE
  • [0058]
    The skin protection cream according to the invention is prepared in a heatable and coolable closed apparatus with a self-withdrawing homogenisator and a heatable metering funnel (preferably in a Koruma multipurpose apparatus).
  • [0059]
    The preparation of phase I is effected in a heatable metering funnel by melting at 75° C. a mixture containing 2% by weight of glyceryl stearate, 4% by weight of cetearyl alcohol, 5% by weight of stearic acid, 1% by weight of paraffin and 1% by weight of triceteareth-4-phosphate, followed by metering this phase with stirring to phase II previously prepared in the heatable and coolable closed apparatus with a self-withdrawing homogenisator. Phase II consists of an aqueous mixture containing 2.5% by weight of propylene glycol, 2.5% by weight of glycerol, 2% by weight of sodium lauroylsarcosinate and 0.3% by weight of allantoin. The amount of water is 79.7% by weight. Homogeneous mixing of phases I and II is to be provided.
  • [0060]
    The metering of phase I is performed at a temperature of 75° C. Both phases are combined with constant stirring at a medium stirring speed, and care must be taken that homogenization is effected uniformly. The temperature is maintained at 75° C. for between 5 and 20 min. The mixture obtained is cooled to a temperature of between 30 and 40° C. with constant stirring.
  • [0061]
    Then, after a temperature of 40° C. has been reached, the further substances may be added. This may include adjusting the pH value to between 7.8 and 8.0. For this purpose, 2-amino-2-methyl-1-propanol is used. Stirring is continued for a sufficient period of time until the pH value has stabilized, followed by filling into suitable storage tanks or into the corresponding spraying containers. In the latter case, 91% of drug is filled together with 9% of butane/propane.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2968628 *Oct 17, 1958Jan 17, 1961Shulton IncPropellant composition
US3666863 *Mar 4, 1969May 30, 1972Medisan AbSkin-treating composition and vehicle for skin-treating agents
US3970584 *Feb 14, 1973Jul 20, 1976S. C. Johnson & Son, Inc.Aerosol package containing a foam-forming emulsion and propellent system
US4137302 *Mar 23, 1977Jan 30, 1979Lever Brothers CompanyCosmetic composition
US4145411 *Feb 23, 1976Mar 20, 1979Colgate-Palmolive CompanyPressurized foaming shaving composition
US4459285 *Feb 25, 1982Jul 10, 1984Societe Anonyme Dite: L'orealCosmetic composition for the treatment of the hair and skin comprising a powder of flowers or flower tops and a cohesion agent
US4569839 *Feb 25, 1982Feb 11, 1986L'orealCosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
US4661340 *Aug 15, 1984Apr 28, 1987Interkemia Vegyipari Gazdasagi TarsasagQuail egg based stabilized foam compositions for cosmetic purposes
US5000938 *Jul 7, 1989Mar 19, 1991Innovatec S.A.Protective aerated foam hand lotion and process for preparing the same
US5086903 *Apr 8, 1991Feb 11, 1992Interrolll Holding AgTandem brake roller system
US5139781 *Feb 13, 1991Aug 18, 1992Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.Topical composition comprising mono- and di-alkyl or alkenyl phosphates and alkylamidopropyl betaines of alkylamphoglycinates
US5278263 *Oct 5, 1992Jan 11, 1994The Goodyear Tire & Rubber CompanySyndiotactic 1,2-polybutadiene synthesis in an aqueous medium utilizing N,N-dibutylformamide as a modifier
US5334387 *Feb 23, 1993Aug 2, 1994Colgate-Palmolive CompanyTopical composition comprising mono and dialkyl phosphates with a cosurfactant
US5439682 *Mar 22, 1993Aug 8, 1995Richardson-Vicks Inc.Combined personal cleansing and moisturizing compositions
US5472686 *Dec 20, 1991Dec 5, 1995Nippon Unicar Company LimitedCosmetic formulations
US5500211 *Sep 22, 1994Mar 19, 1996The Gillette CompanySoap-free self-foaming shave gel composition
US5525588 *Sep 14, 1994Jun 11, 1996Elzabeth Arden Co.Cosmetic composition
US5621012 *Jun 1, 1995Apr 15, 1997Beiersdorf AktiengesellschaftActive compound combinations having a content of glyceryl alkyl ethers and cosmetic and dermatological formulations comprising such active compound combinations
US5674511 *Sep 30, 1996Oct 7, 1997The Procter & Gamble CompanyShelf stable skin cleansing liquid with gel forming polymer, lipid and crystalline ethylene glycol fatty acid ester
US5788972 *Oct 24, 1995Aug 4, 1998L'orealProduct for topical application containing a lipase and an active ingredient precursor
US5882659 *Dec 2, 1996Mar 16, 1999L'orealUse of a polyholoside in a cleaning or make-up-removing composition and composition comprising same
US5902590 *Feb 22, 1995May 11, 1999Henkel Kommanditgesellschaft Auf AktienCosmetic and/or pharmaceutical formulations
USH2013 *May 23, 1997Feb 5, 2002The Procter & Gamble CompanySkin care compositions
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7645803May 9, 2006Jan 12, 2010Foamix Ltd.Saccharide foamable compositions
US7700076Aug 20, 2004Apr 20, 2010Foamix, Ltd.Penetrating pharmaceutical foam
US7704518May 9, 2006Apr 27, 2010Foamix, Ltd.Foamable vehicle and pharmaceutical compositions thereof
US7820145Apr 28, 2004Oct 26, 2010Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8114385Dec 26, 2006Feb 14, 2012Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8119106Jul 8, 2009Feb 21, 2012Foamix LtdFoamable iodine compositions
US8119109Mar 13, 2007Feb 21, 2012Foamix Ltd.Foamable compositions, kits and methods for hyperhidrosis
US8119150Jul 6, 2006Feb 21, 2012Foamix Ltd.Non-flammable insecticide composition and uses thereof
US8343945Jun 7, 2010Jan 1, 2013Foamix Ltd.Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8362091Apr 26, 2010Jan 29, 2013Foamix Ltd.Foamable vehicle and pharmaceutical compositions thereof
US8435498Apr 1, 2010May 7, 2013Foamix Ltd.Penetrating pharmaceutical foam
US8486374Jan 14, 2008Jul 16, 2013Foamix Ltd.Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486375Feb 20, 2012Jul 16, 2013Foamix Ltd.Foamable compositions
US8486376Apr 6, 2005Jul 16, 2013Foamix Ltd.Moisturizing foam containing lanolin
US8512718Feb 12, 2010Aug 20, 2013Foamix Ltd.Pharmaceutical composition for topical application
US8518376Oct 6, 2009Aug 27, 2013Foamix Ltd.Oil-based foamable carriers and formulations
US8518378Sep 14, 2010Aug 27, 2013Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8618081May 4, 2011Dec 31, 2013Foamix Ltd.Compositions, gels and foams with rheology modulators and uses thereof
US8636982Aug 7, 2008Jan 28, 2014Foamix Ltd.Wax foamable vehicle and pharmaceutical compositions thereof
US8703105Mar 11, 2013Apr 22, 2014Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US8709385Jul 14, 2010Apr 29, 2014Foamix Ltd.Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021Mar 6, 2013May 13, 2014Foamix Ltd.Foamable carriers
US8741265Mar 4, 2013Jun 3, 2014Foamix Ltd.Penetrating pharmaceutical foam
US8795635May 12, 2010Aug 5, 2014Foamix Ltd.Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693Nov 29, 2007Aug 5, 2014Foamix Ltd.Compositions with modulating agents
US8840869Apr 28, 2005Sep 23, 2014Foamix Ltd.Body cavity foams
US8865139Jul 9, 2014Oct 21, 2014Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US8871184Oct 1, 2010Oct 28, 2014Foamix Ltd.Topical tetracycline compositions
US8900553Jun 7, 2010Dec 2, 2014Foamix Pharmaceuticals Ltd.Oil and liquid silicone foamable carriers and formulations
US8900554Feb 20, 2012Dec 2, 2014Foamix Pharmaceuticals Ltd.Foamable composition and uses thereof
US8945516Oct 1, 2010Feb 3, 2015Foamix Pharmaceuticals Ltd.Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8992896Aug 27, 2014Mar 31, 2015Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US9050253Apr 7, 2014Jun 9, 2015Foamix Pharmaceuticals Ltd.Oleaginous pharmaceutical and cosmetic foam
US9072667Jan 27, 2012Jul 7, 2015Foamix Pharmaceuticals Ltd.Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9078845 *Jan 20, 2006Jul 14, 2015Kayban Pty LtdAnti-microbial agent
US9101662Oct 3, 2013Aug 11, 2015Foamix Pharmaceuticals Ltd.Compositions with modulating agents
US9161916Dec 31, 2012Oct 20, 2015Foamix Pharmaceuticals Ltd.Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9167813Jan 27, 2012Oct 27, 2015Foamix Pharmaceuticals Ltd.Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259Jun 7, 2006Dec 15, 2015Foamix Pharmaceuticals Ltd.Antibiotic kit and composition and uses thereof
US9265725Jul 5, 2007Feb 23, 2016Foamix Pharmaceuticals Ltd.Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705Jan 8, 2009Apr 26, 2016Foamix Pharmaceuticals Ltd.Sensation modifying topical composition foam
US9439857Dec 1, 2008Sep 13, 2016Foamix Pharmaceuticals Ltd.Foam containing benzoyl peroxide
US9492412Apr 22, 2014Nov 15, 2016Foamix Pharmaceuticals Ltd.Penetrating pharmaceutical foam
US9539208Feb 4, 2014Jan 10, 2017Foamix Pharmaceuticals Ltd.Foam prepared from nanoemulsions and uses
US9549898Oct 2, 2014Jan 24, 2017Foamix Pharmaceuticals Ltd.Oil and liquid silicone foamable carriers and formulations
US9572775Sep 17, 2015Feb 21, 2017Foamix Pharmaceuticals Ltd.Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9622947Jan 8, 2009Apr 18, 2017Foamix Pharmaceuticals Ltd.Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405Mar 11, 2013May 2, 2017Foamix Pharmaceuticals Ltd.Foamable vehicle and pharmaceutical compositions thereof
US9662298Jan 22, 2014May 30, 2017Foamix Pharmaceuticals Ltd.Wax foamable vehicle and pharmaceutical compositions thereof
US9668972Mar 11, 2005Jun 6, 2017Foamix Pharmaceuticals Ltd.Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700Jan 13, 2015Jun 13, 2017Foamix Pharmaceuticals Ltd.Topical tetracycline compositions
US9682021Feb 25, 2014Jun 20, 2017Foamix Pharmaceuticals Ltd.Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9713643May 8, 2014Jul 25, 2017Foamix Pharmaceuticals Ltd.Foamable carriers
US9795564Aug 15, 2013Oct 24, 2017Foamix Pharmaceuticals Ltd.Oil-based foamable carriers and formulations
US20040265240 *Apr 28, 2004Dec 30, 2004Foamix Ltd.Foamable iodine composition
US20050031547 *Apr 28, 2004Feb 10, 2005Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US20050069566 *Aug 4, 2004Mar 31, 2005Foamix Ltd.Foam carrier containing amphiphilic copolymeric gelling agent
US20050074414 *Aug 20, 2004Apr 7, 2005Foamix Ltd.Penetrating pharmaceutical foam
US20050075407 *Aug 20, 2004Apr 7, 2005Foamix Ltd.Foam incorporating eutetic mixture
US20050186147 *Feb 4, 2005Aug 25, 2005Foamix Ltd.Cosmetic and pharmaceutical foam with solid matter
US20050205086 *Mar 11, 2005Sep 22, 2005Foamix Ltd.Retinoid immunomodulating kit and composition and uses thereof
US20050232869 *Mar 11, 2005Oct 20, 2005Foamix Ltd.Nonsteroidal immunomodulating kit and composition and uses thereof
US20050244342 *Apr 6, 2005Nov 3, 2005Foamix Ltd.Moisturizing foam containing lanolin
US20050271596 *May 9, 2005Dec 8, 2005Foamix Ltd.Vasoactive kit and composition and uses thereof
US20050271598 *Apr 28, 2005Dec 8, 2005Foamix Ltd.Body cavity foams
US20060018937 *Apr 26, 2005Jan 26, 2006Foamix Ltd.Steroid kit and foamable composition and uses thereof
US20060140984 *Oct 24, 2003Jun 29, 2006Foamix Ltd.Cosmetic and pharmaceutical foam
US20060193789 *Jan 23, 2006Aug 31, 2006Foamix Ltd.Film forming foamable composition
US20060233721 *Mar 27, 2006Oct 19, 2006Foamix Ltd.Foam containing unique oil globules
US20060269485 *Jun 7, 2006Nov 30, 2006Foamix Ltd.Antibiotic kit and composition and uses thereof
US20060275221 *May 9, 2006Dec 7, 2006Foamix Ltd.Saccharide foamable compositions
US20070020213 *Jul 19, 2006Jan 25, 2007Foamix Ltd.Foamable composition combining a polar solvent and a hydrophobic carrier
US20070020304 *Jul 6, 2006Jan 25, 2007Foamix Ltd.Non-flammable insecticide composition and uses thereof
US20070098647 *Sep 27, 2006May 3, 2007Neubourg Skin Care Gmbh & Co. KgSkin care products
US20070253911 *Mar 13, 2007Nov 1, 2007Foamix Ltd.Foamable compositions, kits and methods for hyperhidrosis
US20070280891 *Dec 26, 2006Dec 6, 2007Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US20070292355 *Apr 4, 2007Dec 20, 2007Foamix Ltd.Anti-infection augmentation foamable compositions and kit and uses thereof
US20070292359 *Jun 7, 2007Dec 20, 2007Foamix Ltd.Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20070292461 *Jan 12, 2007Dec 20, 2007Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US20080044444 *Jul 5, 2007Feb 21, 2008Foamix Ltd.Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080138293 *Aug 20, 2007Jun 12, 2008Foamix LtdCosmetic and pharmaceutical foam
US20080152596 *Aug 20, 2007Jun 26, 2008Foamix Ltd.Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080166303 *Sep 10, 2007Jul 10, 2008Dov TamarkinColored or colorable foamable composition and foam
US20080206155 *Nov 14, 2007Aug 28, 2008Foamix Ltd.Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080206161 *Jan 25, 2008Aug 28, 2008Dov TamarkinQuiescent foamable compositions, steroids, kits and uses thereof
US20080253973 *Jan 8, 2008Oct 16, 2008Foamix Ltd.Sensation modifying topical composition foam
US20080260655 *Feb 4, 2008Oct 23, 2008Dov TamarkinSubstantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080267890 *Jan 20, 2006Oct 30, 2008Kayban Pty Ltd.Anti-Microbial Agent
US20080292560 *Mar 14, 2008Nov 27, 2008Dov TamarkinSilicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US20080299220 *Jan 14, 2008Dec 4, 2008Dov TamarkinHydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20080317679 *Jun 22, 2007Dec 25, 2008Foamix Ltd.Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20090130029 *Nov 21, 2008May 21, 2009Foamix Ltd.Glycerol ethers vehicle and pharmaceutical compositions thereof
US20090175799 *Jan 8, 2009Jul 9, 2009Dov TamarkinColored or colorable topical composition foam
US20090180970 *Jan 8, 2009Jul 16, 2009Foamix Ltd.Foamable composition combining a polar solvent and a hydrophobic carrier
US20100040561 *Aug 20, 2004Feb 18, 2010Foamix Ltd.Penetrating pharmaceutical foam
US20100221195 *May 12, 2010Sep 2, 2010Foamix Ltd.Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20100266510 *Apr 26, 2010Oct 21, 2010Foamix Ltd.Foamable Vehicle and Pharmaceutical Compositions Thereof
US20100284938 *Apr 1, 2010Nov 11, 2010Foamix Ltd.Penetrating pharmaceutical foam
US20100310476 *Jun 7, 2010Dec 9, 2010Foamix Ltd.Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US20110002857 *Sep 14, 2010Jan 6, 2011Foamix Ltd.Oleaginous pharmaceutical and cosmetic foam
US20110097279 *Dec 21, 2010Apr 28, 2011Foamix Ltd.Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20110212033 *Jun 7, 2010Sep 1, 2011Foamix Ltd.Oil and liquid silicone foamable carriers and formulations
Classifications
U.S. Classification424/401
International ClassificationA61K8/96, A61K8/891, A61K8/20, A61K8/34, A61K8/362, A61K8/89, A61K8/98, A61K8/44, A61K8/30, A61K8/97, A61Q19/00, A61K9/12, A61K8/37, A61K8/60, A61K8/40, A61K8/31, A61K8/36, A61K8/365, A61K8/00, A61K8/42, A61K8/04, A61K8/02
Cooperative ClassificationA61Q19/00, A61K8/556, A61K45/06, A61K31/20, A61K8/342, A61Q17/00, A61K8/361, A61K8/97, A61K8/37, A61K8/046
European ClassificationA61K31/20, A61K8/97, A61K8/04F, A61K45/06, A61Q19/00, A61K8/34C, A61K8/36C, A61K8/37, A61K8/55F
Legal Events
DateCodeEventDescription
Apr 12, 2007ASAssignment
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUBOURG, STEPHANIE;REEL/FRAME:019161/0303
Effective date: 20070320
May 7, 2007ASAssignment
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY
Free format text: CORRECTIVE ASSIGNMENT TO CHANGE "ISSUED PATENT NUMBER" UNDER SECTION 4 FROM "6423434" TO -6423323--(PREVIOUSLY RECORDED AT R/F 019161/0303);ASSIGNOR:NEUBOURG, STEPHANIE;REEL/FRAME:019254/0492
Effective date: 20070320
Owner name: NEUBOURG SKIN CARE GMBH & CO. KG, GERMANY
Free format text: CORRECTIV;ASSIGNOR:NEUBOURG, STEPHANIE;REEL/FRAME:019254/0492
Effective date: 20070320